Related Experiment Video
Updated: Jul 14, 2026

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
Matrix metalloproteinase-3 and coronary remodelling: implications for unstable coronary disease
Anthony J White1, Stephen J Duffy, Anthony S Walton
1Baker Heart Research Institute and The Department of Cardiovascular Medicine, Alfred Hospital, Melbourne, Australia.
Insights
The MMP-3 6A allele is linked to unstable coronary syndromes. This genetic variant promotes plaque buildup and outward vessel remodeling, increasing heart attack risk.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Biomarkers in Atherosclerosis
Background:
- Matrix metalloproteinases (MMPs) are implicated in cardiovascular disease.
- The MMP-3 gene polymorphism (-1171, 5A/6A) is a potential predictor of unstable coronary syndromes.
- Understanding genetic predispositions can aid in risk stratification for coronary artery disease (CAD).
Purpose of the Study:
- To investigate the association between the MMP-3 polymorphism (-1171, 5A/6A) and coronary plaque characteristics.
- To determine if this polymorphism predicts unstable clinical presentation in patients with coronary artery disease.
Main Methods:
- Coronary intravascular ultrasound and angiography were used to assess plaque burden and stenosis in 40 de novo CAD patients.
- Patients were categorized into unstable coronary syndrome (n=19) or stable angina pectoris (n=21).
- A validation cohort (n=161) and the total population (n=201) were analyzed to confirm findings.
Main Results:
- The MMP-3 6A allele was significantly more prevalent in patients with unstable coronary syndromes (p=0.027).
- 6A allele carriers exhibited greater plaque burden, positive coronary remodeling, and higher plasma MMP-3 concentrations.
- This association remained significant and independent of conventional risk factors in validation and total cohorts (p=0.007).
Conclusions:
- The MMP-3 6A allele is associated with positive coronary remodeling and increased plaque burden.
- Carrying the 6A allele increases susceptibility to unstable coronary syndromes in humans.
- This polymorphism serves as a potential genetic marker for predicting adverse cardiovascular events.
Objectives:
Matrix metalloproteinases (MMPs) are plausible candidates for prediction of unstable coronary syndromes. We hypothesised that the MMP-3 polymorphism (- 1171, 5A/6A) would relate to coronary plaque characteristics and unstable clinical presentation.
Methods And Results:
Forty patients with de novo presentation of coronary artery disease (CAD) were classified into unstable coronary syndrome (n=19) or stable angina pectoris (n=21). On coronary intravascular ultrasound, patients with unstable disease had a greater plaque burden, more positive (outward) coronary remodelling, and all but one were MMP-3 6A allele carriers (p=0.027 compared with stable). The relationship between the 6A allele and unstable presentation was substantiated in a validation cohort of 161 CAD patients (58 stable and 103 unstable) and in the total population of 201 CAD patients (79 stable and 122 unstable, p=0.007), and was independent of conventional risk factors. Furthermore, 6A allele carriers had a higher plasma MMP-3 concentration (15.8+/-12.5 versus 11.7+/-7.2 ng/mL, p=0.01), maximum coronary stenosis on angiography (89+/-15% versus 80+/-23%, p=0.02), plaque area (12.0+/-5.2 versus 7.5+/-3.6 mm(2), p=0.03), percentage plaque burden (82+/-7 versus 71+/-13%, p=0.003), and remodelling ratio (1.03+/-0.23 versus 0.83+/-0.12, p=0.003).
Conclusions:
The MMP-3 6A allele promotes positive coronary remodelling, greater plaque burden, and increased susceptibility to unstable coronary syndromes in humans.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
A...
Coronary Artery Disease II: Pathophysiology
Myocarditis I: Introduction
Myocarditis III: Medical Management
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease III: Clinical Manifestations
